HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

NCT06595563 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

87

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Metastatic Breast Cancer
HER2-positive Advanced Breast Cancer

Interventions

DRUG: Trastuzumab emtansine

Sponsor

Jules Bordet Institute

Collaborators

[object Object]